Scalper1 News
Leerink Partners upgraded Teva Pharmaceutical Industries (TEVA) to outperform Thursday, sending the stock up to a three-year high on the stock market today. Analyst Jason Gerberry wrote that his survey of the multiple-sclerosis market showed strong uptake of the new 40-milligram, thrice-weekly version of Teva’s Copaxone, estimating that about 40% will have switched to it after two years. This is crucial to the company retaining some market share Scalper1 News
Scalper1 News